+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Insulin Glargine"

From
From
From
Insulin biosimilars Global Market Report 2024 - Product Thumbnail Image

Insulin biosimilars Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
From
Insulin Intelligence Center 2012-2023 - Product Thumbnail Image

Insulin Intelligence Center 2012-2023

  • Report
  • February 2024
  • Global
From
Diabetes Drug Intelligence Center 2012-2023 - Product Thumbnail Image

Diabetes Drug Intelligence Center 2012-2023

  • Report
  • February 2024
  • Global
From
From
From
Human Insulin Market Forecasts from 2023 to 2028 - Product Thumbnail Image

Human Insulin Market Forecasts from 2023 to 2028

  • Report
  • November 2023
  • 144 Pages
  • Global
From
From
Global Insulin Delivery Devices Market Outlook, 2028 - Product Thumbnail Image

Global Insulin Delivery Devices Market Outlook, 2028

  • Report
  • November 2023
  • 190 Pages
  • Global
From
Global Insulin Delivery Devices Market Overview, 2023-2028 - Product Thumbnail Image

Global Insulin Delivery Devices Market Overview, 2023-2028

  • Report
  • November 2023
  • 110 Pages
  • Global
From
Loading Indicator

Insulin Glargine is a long-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. It is administered by subcutaneous injection and works by helping the body use glucose more efficiently. Insulin Glargine is a recombinant human insulin analog that is modified to reduce its solubility and prolong its action. It is available in both prefilled pens and vials. Insulin Glargine is a key drug in the Endocrine and Metabolic Disorders Drugs market. It is used to treat diabetes, a chronic condition that affects millions of people worldwide. It is an important part of diabetes management, helping to control blood sugar levels and reduce the risk of complications. Companies in the Insulin Glargine market include Sanofi, Eli Lilly, Novo Nordisk, Merck, and Boehringer Ingelheim. Show Less Read more